102 related articles for article (PubMed ID: 8317894)
1. Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro.
Tominaga T; Yoshida Y; Matsumoto A; Hayashi K; Kosaki G
Anticancer Res; 1993; 13(3):661-5. PubMed ID: 8317894
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
3. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice.
Brünner N; Bronzert D; Vindeløv LL; Rygaard K; Spang-Thomsen M; Lippman ME
Cancer Res; 1989 Mar; 49(6):1515-20. PubMed ID: 2924304
[TBL] [Abstract][Full Text] [Related]
4. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
5. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
6. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
8. The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells.
Horii Y; Takei H; Koibuchi Y; Horiguchi J; Maemura M; Iino Y; Morishita Y
Oncol Rep; 2006 May; 15(5):1191-5. PubMed ID: 16596185
[TBL] [Abstract][Full Text] [Related]
9. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
10. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
Coradini D; Biffi A; Cappelletti V; Di Fronzo G
Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
[TBL] [Abstract][Full Text] [Related]
11. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
12. Influence of cyclopropyl antiestrogens on the cell cycle kinetics of MCF-7 human breast cancer cells.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1995; 15(6B):2529-32. PubMed ID: 8669818
[TBL] [Abstract][Full Text] [Related]
13. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
15. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
[TBL] [Abstract][Full Text] [Related]
16. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
17. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells.
Bowen D; Southerland WM; Hawkins M; Johnson DH
Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
Asaishi K; Tominaga T; Abe O; Izuo M; Nomura Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):91-9. PubMed ID: 8422190
[TBL] [Abstract][Full Text] [Related]
19. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
[TBL] [Abstract][Full Text] [Related]
20. [Toremifene sensitized the effect of adriamycin on human breast cancer cell lines].
Nakagomi H; Furuya K; Hagiwara J; Nishio T; Watanabe K; Muto S; Takano K; Tada Y
Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():454-8. PubMed ID: 9589052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
